Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine (GalaNic)

University of Maryland Baltimore (UMB)

Status: Completed

Conditions: Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor

Treatments: Drug: Placebo patch & galantamine capsule; Drug: Placebo patch & placebo capsule; Drug: Nicotine patch & placebo capsule; Drug: Nicotine patch and galantamine capsule

Study type: Interventional

Funder types: Other

Identifiers

NCT02420327

HP-00057097

Details and patient eligibility

About

The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4 mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24 mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the presence of this low dose of galantamine.

Full description

Healthy non-smokers will be screened for study eligibility and receive training on three different attention tasks. Over four test session, participants will then perform these tasks after receiving (1) a placebo patch and a placebo capsule, (2) a nicotine patch (7 mg/24 hrs) and a placebo capsule, (3) a placebo patch and a galantamine capsule, and (4) a nicotine patch and a galantamine capsule. The four test session are performed on separate days and take approximately 7 hours each. During the first 5 hours, the participant may read or watch TV while nicotine and/or galantamine are being absorbed. During the last two hours, the participant will perform the attention tasks on a computer. The investigators hypothesize that performance-enhancing effects of nicotine, which were documented in previous research, will be larger in the presence than in the absence of galantamine. This proof-of-concept would have implications for the development of drugs for the treatment of conditions such as Alzheimer's disease or schizophrenia.

Enrollment: 43 patients

Sex: All

Ages: 21 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged 21 to 55 years.
• No exposure to any nicotine-containing product in the last year.
• Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.
• Normal or corrected to normal vision (at least 20/80).
• Body weight 110-220 lbs.

Exclusion criteria

• Pregnant or breast-feeding.
• Drug or alcohol abuse or dependence currently or in the last 2 years.
• DSM Axis I mood, anxiety or psychotic disorder.
• Cardiovascular or cerebrovascular disease, such as history of myocardial infarction and ischemia, heart failure, angina, stroke, severe arrhythmias, or EKG abnormalities (Wolf-Parkinson-White syndrome, Complete left bundle branch block, PR interval <120 ms or >200 ms, Prolonged QT interval (corrected) >500 ms, Cardiac arrhythmias as defined by PACs >3 per min or PVCs >1 per min).
• Uncontrolled hypertension (resting systolic BP above 140 or diastolic above 90 mm Hg).
• Hypotension (resting systolic BP below 90 or diastolic below 60).
• Significant kidney or liver impairment.
• Moderate to severe asthma.
• Obstructive pulmonary disease.
• Type I or II diabetes.
• Use of any centrally active medications; any peripherally acting cholinergic medications; cimetidine; ketoconazole; erythromycin; quinidine, or chronic nonsteroidal anti-inflammatory drugs.
• History of or current neurological illnesses, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome.
• Learning disability, mental retardation, or any other condition that impedes cognition.
• Heart rate <55 bpm.
• Current or history of gastric ulcer disease.
• Any surgeries requiring full anesthesia scheduled within 2 weeks of any of the study test sessions.
• Anemia.
• Inability to perform the Rapid Visual Information Processing Task.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Triple Blind

---

43 participants in 4 patient groups

Placebo patch and placebo capsule

Experimental group

Description:

On the double-placebo test day, participants receive a placebo patch and a placebo capsule.

Treatment:

Drug: Placebo patch & placebo capsule

Nicotine patch and placebo capsule

Experimental group

Description:

On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.

Treatment:

Drug: Nicotine patch & placebo capsule

Placebo patch and galantamine capsule

Experimental group

Description:

On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.

Treatment:

Drug: Placebo patch & galantamine capsule

Nicotine patch and galantamine capsule

Experimental group

Description:

On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.

Treatment:

Drug: Nicotine patch and galantamine capsule